# Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)

> **NCT04807478** · — · WITHDRAWN · sponsor: **Fresenius Kabi**

## Conditions studied

- Parenteral Nutrition Associated Liver Disease
- Essential Fatty Acid Deficiency
- Neurocognitive Deficit
- Malnutrition
- Pediatric ALL

## Interventions

- **DRUG:** Omegaven® (fish oil triglycerides) Injectable Emulsion

## Key facts

- **NCT ID:** NCT04807478
- **Lead sponsor:** Fresenius Kabi
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-01
- **Primary completion:** 2028-05-01
- **Final completion:** 2029-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** New study protocol under development
- **Last updated:** 2022-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04807478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04807478, "Safety of Omegaven in Pediatric Patients With Parenteral Nutrition-Associated Cholestasis (PNAC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04807478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*